Ron Shapiro, MD
Transplant Surgery · New York, NYNPI 1720053911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,730 of the $16,171 with a category attached, or 60.2%. CSL Behring accounts for 74.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $12,151 and has fallen 81.8% since, to $2,208 in 2025.
Across 13 payments — averaging $1243.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$12K
- Sanofi US Services Inc.$2K
- Modernatx, Inc.$1K
- AstraZeneca$150
- Takeda Pharmaceuticals U.S.A., Inc.$136
- Sanofi$111
- plus $36 from 1 others
Across 16 payments — averaging $340.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$5K
What the payments were for
- Consulting fees$3,69823%
- Speaking & faculty fees$9,73060%
- Travel & lodging$2,29214%
- Food & beverage$4513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 6 | $12,040 |
| Sanofi US Services Inc. | 1 | $2,208 |
| Modernatx, Inc. | 1 | $1,490 |
| AstraZeneca | 1 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $136 |
| Sanofi | 1 | $111 |
| One Lambda, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUROCK$2,208
- SOLIRIS$150
- THYMOGLOBULIN$111
How this compares
$16,171 in reported general payments places this provider in the 80th percentile of 72 transplant surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in New York
- Kishore IyerNew York$95K
- Jason HawksworthNew York$91K
- Parissa TabrizianNew York$74K
- Lloyd RatnerNew York$32K
- Hautien LiouNew York$31K
- Karim HalazunNew York$28K
- Myron SchwartzNew York$27K
- Gabriel GondolesiNew York$15K
- Lewis TepermanNew York$13K
- Babak OrandiNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.